Moderna loses $5B in market value after new data on RSV vaccine



Months before Moderna Inc. plans to launch its new RSV vaccine later this year, new data shows it gets less effective than its competitors over time.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *